Skip to main content
. 2011 Apr 5;19(7):1312–1322. doi: 10.1038/mt.2011.35

Figure 3.

Figure 3

The folate-packaging RNA (pRNA) nanoparticle targets FR+ tumors upon systemic administration. (a) HeLa xenograft tumor-bearing nude mice were injected with 15 nmol (~24 mg/kg) of KT-105 (Folate-AlexaFluor647-labeled pRNA nanoparticle) through the tail-vein (right). The control mice were injected with either phosphate-buffered saline (PBS) (left) or with folate (intraperitoneal (i.p.), 10 mg/kg) 10 minutes before KT-105 injection (middle). The mice were euthanized 24 hours after injection and whole-body imaging was conducted using IVIS Lumina station. (b) Following whole-body imaging, the mice were dissected and the major organ were isolated for imaging. H, heart; I, intestine; K, kidney; L, lung; Lv, liver; M, muscle; S, spleen; T, tumor. (c) KB xenograft tumor-bearing nude mice were injected with 15 nmol (24 mg/kg) (lower panel) or 3.75 nmol (upper panel) (~6 mg/kg) of KT-105 through the tail vein. And organ were isolated and imaged as described above.